https://www.selleckchem.com/pr....oducts/CP-690550.htm
Plasma luteinizing hormone (LH) concentration decreased 90% in 90% of patients receiving ASP1707, with a rapid decrease to less then 1 IU/L at week 1 that remained stable throughout the treatment.Conclusion In the current study, ASP1707 did not demonstrate a clinical benefit.Objective To study the influence of butyphthalide combined with urinary kallikrein in acute cerebral infarction (ACI) treatment on neuro-cytokines and indicators of vascular endothelial function, observe the curative effect and adverse effects, and discuss
Like
Comment
Share
